Literature DB >> 29676235

Current and Promising Therapies in Autosomal Recessive Ataxias.

Vincent Picher-Martel1,2, Nicolas Dupre2.   

Abstract

BACKGROUND &
OBJECTIVE: Ataxia is clinically characterized by unsteady gait and imbalance. Cerebellar disorders may arise from many causes such as metabolic diseases, stroke or genetic mutations. The genetic causes are classified by mode of inheritance and include autosomal dominant, X-linked and autosomal recessive ataxias. Many years have passed since the description of the Friedreich's ataxia, the most common autosomal recessive ataxia, and mutations in many other genes have now been described. The genetic mutations mostly result in the accumulation of toxic metabolites which causes Purkinje neuron lost and eventual cerebellar dysfunction. Unfortunately, the recessive ataxias remain a poorly known group of diseases and most of them are yet untreatable.
CONCLUSION: The aim of this review is to provide a comprehensive clinical profile and to review the currently available therapies. We overview the physiopathology, neurological features and diagnostic approach of the common recessive ataxias. The emphasis is also made on potential drugs currently or soon-to-be in clinical trials. For instance, promising gene therapies raise the possibility of treating differently Friedreich's ataxia, Ataxia-telangiectasia, Wilson's disease and Niemann-Pick disease in the next few years. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Recessive ataxia; ataxia with oculomotor apraxia; ataxia with vitamin E deficiency; ataxia-telangiectasia; autosomal recessivezzm321990spastic ataxia of charlevoix-saguenay; cerebrotendinous xantomatosis; friedreich's ataxia; niemann-pick disease type C; refsum's disease; wilson'szzm321990disease.

Mesh:

Substances:

Year:  2018        PMID: 29676235     DOI: 10.2174/1871527317666180419115029

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  3 in total

Review 1.  Discovery of Therapeutics Targeting Oxidative Stress in Autosomal Recessive Cerebellar Ataxia: A Systematic Review.

Authors:  Sze Yuen Lew; Michael Weng Lok Phang; Pit Shan Chong; Jaydeep Roy; Chi Him Poon; Wing Shan Yu; Lee Wei Lim; Kah Hui Wong
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-19

Review 2.  Recent Advances in the Treatment of Cerebellar Disorders.

Authors:  Hiroshi Mitoma; Mario Manto; Jordi Gandini
Journal:  Brain Sci       Date:  2019-12-23

Review 3.  Documenting manifestations and impacts of autosomal recessive spastic ataxia of Charlevoix-Saguenay to develop patient-reported outcome.

Authors:  Marjolaine Tremblay; Laura Girard-Côté; Bernard Brais; Cynthia Gagnon
Journal:  Orphanet J Rare Dis       Date:  2022-10-01       Impact factor: 4.303

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.